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Background: Increasing numbers of people in the UK are living with recurrent or metastatic cancer, many of
whom experience reduced quality of life resulting from the physical and psychosocial consequences of cancer and
its treatment. While drug treatments are important at alleviating some symptoms, there is increasing evidence of
the benefits of exercise in enhancing quality of life and health outcomes. Walking is an inexpensive and accessible
form of exercise. To our knowledge, no studies have investigated whether a walking intervention is sufficient to
enhance quality of life and alleviate symptoms in people with recurrent or metastatic cancer across a range of
tumor types. This paper describes the CanWalk study protocol, which aims to assess the feasibility and acceptability
of undertaking a randomized controlled trial of a community-based walking program to enhance quality of life and
well-being in people with recurrent or metastatic cancer.
Methods: A mixed methods feasibility study includes an exploratory two-center randomized controlled trial and
qualitative interviews. A minimum of 60 participants will be recruited from two London NHS Trusts and randomized
1:1 between the walking intervention and standard care using minimization. The walking intervention consists of
the initial provision of written/online information followed by a short motivational interview. Participants are
instructed to walk for 30 min on alternate days and attend an organized volunteer-led walk once a week. Half of all
participants will be asked to use a pedometer. Postal questionnaires will be completed at baseline (pre-randomization)
and at 6, 12 and 24 weeks. A subsample of participants and stakeholders will be interviewed at the end of the study.
Results: Primary outcomes will be the acceptability and feasibility of the intervention and trial. A range of secondary
outcome assessments needed to design a main study, including estimates of recruitment, adherence and variability in
quality of life, will be evaluated.
Conclusions: Data from this study will be used to refine the walking intervention, investigate the acceptability of the
intervention and study design, and determine the most appropriate outcome measures thereby providing estimates of
the factors needed to design the main study.
Trial registration: ISRCTN42072606.
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Table 1 Walking intervention for people with recurrent or
metastatic cancer: definitions of recurrent or metastatic
disease
Primary tumor Definition
Breast Metastatic disease - stage 4, for example,
visceral, bone, soft tissue, and so on.
Not local recurrence
Colorectal Metastatic - stage 4 - M1
Gynecological Ovary - symptomatic stage 3/4/recurrence
Cervix - stage 3/4
Endometrial - stage 3/4
Vulva - stage 3/4
Hematological Lymphoma (high and low grade) within first
6 months of relapse, myeloma
Head and neck Metastatic disease, recurrence
Melanoma Stage 3/4
Prostate Distant metastatic disease or bone
metastases (T3, N1, M1)
Upper gastrointestinal Stage 3/4, oesophago-gastric
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Two million people are living with cancer in the UK today
[1], and it is predicted that the number will increase to four
million over the next 30 years [2]. The precise number of
people living with recurrent cancer (the cancer has
returned after treatment has ended) or metastatic cancer
(the cancer has spread from the place where it first started)
is unknown, although there is some evidence that the life
expectancy of this group is also increasing [3]. Nevertheless,
people with recurrent or metastatic cancer face a number
of health challenges including psychological disorders [4]
and physical symptoms, including pain, fatigue, and appe-
tite loss [5]. While drug treatments are important at allevi-
ating some of these symptoms, two recent systematic
reviews identified the important potential contribution of
exercise in enhancing the quality of life (QoL) in those with
recurrent or metastatic cancer [6,7]. Specifically, programs
that include regular walking for more than 30 min may gen-
erate improvements in QoL, physical functioning, and fatigue
and are acceptable and well tolerated [6,8]. However, many
of the interventions reviewed included different types of
physical activity, were supervised, and required attendance
at specialist exercise facilities, which may limit their accept-
ability or economic sustainability in the long term.
While many people with cancer may be hesitant to exer-
cise [9], research from primary care demonstrates the ef-
fectiveness of brief advice, supported by written materials,
at increasing physical activity levels [10]. Walking is an in-
expensive form of exercise, it can be undertaken alone or in
a group, and has demonstrated significant health benefits -
including for cancer [11]. An additional advantage of walk-
ing is that it is not restricted to a specific facility or setting
and has been shown to be associated with longer-term
changes in behavior [10]. Preliminary results from a ran-
domized pilot walking intervention in Sweden among
men with prostate cancer suggest that regular group walk-
ing has positive effects on both quality of life and inflam-
matory and metabolic biomarkers [12]. However, no
studies to date have investigated whether a walking inter-
vention on its own is sufficient to enhance the physical
and psychological well-being of people with recurrent or
metastatic cancer across a range of tumor types.
Here, we describe the protocol of the CanWalk study,
which aims to assess the feasibility and acceptability of
undertaking a randomized controlled trial of a community-
based walking program to enhance quality of life in people
with recurrent or metastatic cancer. The study will promote
a walking intervention, assess whether participants find
it acceptable and evaluate whether a full randomized
controlled trial is warranted and feasible. Specific objec-
tives include:
1. The development of the walking intervention to
encourage intervention uptake [13];2. To investigate the acceptability to participants of a)
the walking intervention, b) the study materials, and
c) being randomized to intervention or control; and
to assess d) the acceptability and timing of the
selected outcome measures, and e) use of
pedometers to enhance and measure adherence;
3. To provide estimates of key aspects of trial design
needed to design a full-scale randomized trial
design, if warranted, including; a) number of eligible
participants, b) recruitment rate, c) retention rate,
d) response rates to initial and follow up questionnaires,
e) the utility of objective and subjective methods to
assess adherence to the walking intervention, and




This is a mixed methods [14] feasibility study based on an
exploratory two-center randomized controlled trial (RCT)
with nested qualitative interviews. The study is registered
with the International Standard Randomized Control Trial
Number Register (ISRCTN42072606). Participants will be
randomized, using a central online system, 1:1 between the
walking intervention and standard care using minimization
(based on age, sex, and physical activity levels).
Setting and participants
The study will be undertaken in two large London NHS
Foundation Trusts. Participants are eligible for the study
if they i) are 16 years or over, ii) have a diagnosis of
breast, colorectal, upper gastrointestinal, gynecological,
hematological, head and neck, melanoma, or prostate
Harris et al. Pilot and Feasibility Studies  (2015) 1:7 Page 3 of 7cancer with recurrent or metastatic disease, iii) meet the eli-
gibility criteria for specific cancer diagnoses (Table 1), and
iv) are able to walk for a minimum of 30 min un-
aided. Exclusion criteria are i) having bone metastases
which the responsible health-care professional con-
siders a contraindication to participating in the walk-
ing intervention; and ii) unable to speak and
understand English.
Figure 1 shows the flow of participants through the
study. Participants will be screened for eligibility byHealth-care professionals/resear
potentialparticipants abouts
provide information pack to
patients
Potential participants read in
sheet. If interested, comp
permission to contact form a
the researcher
Researcher contacts, describe
assesses willingness to parti
patients if they can walk for a 
mins
Randomization
Intervention group (n=30): brief (approximately
10 min) motivational interview
Half wear a pedometer/record steps taken for 7
days
Intervention group:walk for a
minimum of 30 min on alternate
days, including one Walking for
Health group activity per week.
Participants complete ques
where appropriate 
pedometer/record steps at 





Patient consent and completes
questionnaire
Figure 1 Walking intervention for people with recurrent or metastatitheir health-care professional (that is, nurses or doc-
tors) as they visit clinics or via hospital records.
Health-care professionals or researchers will describe
the study to those identified during a clinic attend-
ance and where appropriate provide a study informa-
tion pack comprising an invitation letter, information
sheet, permission to contact form, a unique study
identification number, and postage paid envelope.
Those identified via hospital records will be sent the









Control group (n=30): continue with
usual activities (informed by telephone)
Half wear a pedometer/record steps
taken for 7 days 
tionnaires and
wear a





Excluded  not eligible/ not
interested
 willing
Excluded  no informed consent
Attrition  no baseline assessment
Attrition: lost to follow up/
withdrawn
 baseline (T0)
c cancer: flowchart of study protocol.
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record reasons for ineligibility and reasons for declining
participation.
Patients who are interested in participating in the
study will be asked to send their permission to con-
tact form directly to the study researcher, giving con-
sent for the researcher to make telephone contact to
describe the study further, assess their willingness to
participate, and check whether they can walk for a
minimum of 30 min. Those who can, and are still in-
terested in the study, will be sent a consent form,
general practitioner (GP) form (to ascertain the de-
tails of their family doctor and permission for the re-
searchers to write to inform their GP of their
participation in the study), and a baseline question-
naire (T0). Possible outcomes are (1) eligible and will-
ing to participate, (2) eligible and unwilling to
participate, and (3) ineligible. Again, wherever pos-
sible, reasons for declining participation and ineligibil-
ity will be recorded.
The intervention
The intervention comprises a brief (approximately 10-
min) telephone or face-to-face session, based on the
UK’s National Institute for Health and Clinical Excel-
lence (NICE) guidance on promoting physical activity
in primary care [13]. The study will utilize the preex-
isting Walking for Health program, a network of UK-
wide, freely available walking groups provided by
MacMillan Cancer Support and The Ramblers [15].
Participants in the intervention group will be asked
to participate in at least one Walking for Health
group activity per week and undertake walking for at
least 30 min on alternate days over 3 months, either
independently or with Walking for Health groups.
Walking for Health’s volunteers lead more than 3,000
short walks (lasting approximately 30 min to 1 h)
throughout the UK every week. The researcher will
assess the patient’s readiness to adhere to the walking
intervention and, using motivational interviewing
techniques, stimulate their use of study materials as a
means to increase physical activity. Increasingly used
in health-care settings, motivational interviewing is a
patient-centered, counseling style that augments an
individual’s motivation to change behavior and move
toward a specific goal [16]. It explores the person’s
own reasons for change and focuses on their
strengths, not just the obstacles and weaknesses asso-
ciated with change [13,16]. Study materials will be
provided in print and online formats to reinforce the
intervention. Information on local Walking for Health
groups will be provided, including details of the seven
Walking for Health coordinators in South East
London and how to find out about walks elsewhere.The intervention will be delivered by researchers
trained in motivational interviewing. An expert in
motivational interviewing will provide supervision to
the researchers during this process to ensure adher-
ence to operational procedures and the principles of
motivational interviewing. Using random selection,
intervention sessions will, with consent, be audio re-
corded to ensure fidelity to the intervention manual.
Comparator group
Participants in the comparator group will be asked to
continue their activities as usual during the study (stand-
ard care).
Assessments
Participants will complete postal questionnaires at base-
line (T0) and at 6 (T1), 12 (T2), and 24 (T3) weeks fol-
lowing recruitment to the study. Two postal reminders
will be sent to non-responders. Table 2 provides an over-
view of the questionnaires that will be completed at each
assessment with a rationale for their use. Additionally,
those in the intervention group will be asked to record
their Walking for Health participation - including date
and location of walks attended - on a simple form.
Semi-structured telephone interviews will be conducted
with ten participants (five per study group) to assess the
acceptability of the intervention, randomization, and
evaluation of the study methods. At the end of the inter-
vention, a maximum of ten stakeholders (that is, com-
munity group coordinators/walk leaders, clinical nurse
specialists, research nurses and hospital doctors) will be
interviewed by the study researchers (JH, VT) to explore
the acceptability of the walking intervention from a pro-
fessional perspective.
Pedometers
Pedometers will be used to assess adherence to the
walking intervention and objectively compare the
amount walked by people in the intervention group
with that walked in the control group. However, they
are also an inexpensive and effective intervention to
increase levels of physical activity [17]. In order to
control for the impact of pedometers on walking be-
havior, only half of the participants in the interven-
tion and control groups will be randomly allocated
with pedometers. This is because wearing a pedom-
eter might increase participants walking regardless of
whether they are in the intervention or control
group. They will be asked to wear them for seven
consecutive days at each assessment point (baseline
pedometer data will be provided once the research
team has received a signed consent form) and to
complete a form recording how many steps they
took over the 7-day period.
Table 2 Walking intervention for people with recurrent or metastatic cancer: questionnaire measures by assessment point
Measures included in the study questionnaire Assessment point
Description T0 (Baseline) T1 (6 weeks)1 T2 (12 weeks)1 T3 (24 weeks)1
Functional assessment of cancer therapy- general (FACT-G) [18] ✓ ✓ ✓ ✓
• Assesses emotional and physical quality of life in the past 7 days
Depression, anxiety, stress scales - 21 (DASS-21) [19] ✓ ✓ ✓ ✓
• Assesses the frequency and severity of symptoms over the past 7 days
General practice physical activity questionnaire (GPPAQ) [20] ✓ ✓ ✓ ✓
• Assesses physical activity levels (classified as active, moderately active,
moderately inactive, inactive) in the past 7 days
Scottish physical activity questionnaire (SPAQ) [21] ✓ ✓ ✓ ✓
• Captures 7-day recall of all leisure and occupational physical activity
Spinal cord injury exercise self-efficacy scale (ESES) [22] ✓ ✓ ✓ ✓
• Assesses current exercise self-efficacy
Brief fatigue inventory (BFI) [23] ✓ ✓ ✓ ✓
• Assesses severity of fatigue and any impact on functioning in the previous
24 hours
Eastern Cooperative Oncology Group (ECOG) [24] ✓ ✓ ✓ ✓
• Measures current performance status, how disease is progressing and affects
daily living activities
Motivational ruler [25] ✓ ✓ ✓ ✓
• Includes two visual 100 mm visual analog scales to measure current
importance and confidence in walking
Patient reported demographics and clinical history ✓
• Study specific measure includes sex, age, marital status, education, long-standing
health conditions etc.
Adverse outcomes and events (intervention only) ✓ ✓
End of study questionnaire ✓
• Effects on quality of life (intervention only); usefulness of information;
achievement of physical activity goals; satisfaction with study/intervention; free
text comments about the study
1Randomization occurs after the baseline questionnaire has been returned. Therefore, follow-up questionnaire timings are as follows: control group - from the date
of the post-randomization telephone call (for example, informing them they are in the control); intervention group - from the date of the motivational interview
telephone call.
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The primary outcomes are whether participants find
the study and intervention acceptable and whether a
full randomized controlled trial is warranted and
feasible.
Secondary outcomes
The secondary outcomes are the refinement of the walking
intervention based on views from participants and stake-
holders and estimates of key aspects of trial design needed
to design a full-scale randomized trial design, if warranted,
including the following:
– The number of eligible participants, recruitment and
retention rate, and response rates to initial and
follow-up questionnaires– The utility of the objective (pedometer) and
subjective (self-report) methods to assess adherence
to the walking intervention
– Estimates of the variability of the QoLSample size
For the feasibility trial, we aim to consecutively recruit a
minimum of 30 patients with recurrent or metastatic
cancer to both the control and intervention groups (60
patients in total). A sample size of 30 per arm will be
sufficient to estimate the standard deviation of our QoL
outcomes and allow estimation of the true treatment dif-
ference. The latter is needed to perform a power calcula-
tion for the main study. A definitive sample size of a
large-scale RCT will be determined from the results of
this trial.
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All quantitative data will be double entered and subjected
to basic descriptive statistical tests, including calculation
of means and frequencies; 95% confidence intervals will
be presented to display the imprecision in QoL measures.
Independent t-tests and χ2 tests will be used for two-
group measure comparisons. Their paired equivalents will
be used to analyze changes in outcome measures between
baseline and follow-up. Rates for process measures (for
example, recruitment, attrition) will be calculated.
Reasons for non-participation and attrition will be
collected to inform future recruitment and retention
strategies. We will also collect data on age and gen-
der, with consent, from all eligible people, regardless
of whether they choose to participate or not, to ex-
plore whether participation rate varies according to
these variables.
Audio recordings of interviews will be transcribed ver-
batim and analyzed using framework analysis; a widely
used matrix-based method for collating, reviewing, and
understanding qualitative data [26]. All data will be
stored securely, and raw data will only be accessible to
the study chief investigator (JA) and researchers (JH,
VT).Serious adverse events reporting and monitoring
It is not anticipated that there will be any risk to partici-
pants. With permission, the researchers will write to all
participants GPs to inform them of their participation
on the study. Data on unexpected and serious adverse
events will be collected at assessments T1 and T2. Any
serious adverse events deemed to be related to the inter-
vention or due to participation in the study will be re-
ported to the chief investigator within 24 h of the team
learning of its occurrence.Project management
The management of the feasibility study will be the re-
sponsibility of the research management group, compris-
ing of the chief investigator, all co-applicants, and all
research staff. Operational management will be the re-
sponsibility of the research team comprising of the chief
investigator and research staff, meeting once a week to
ensure adherence to planned timescale, adherence to the
intervention and detailed plans for data management
and analysis. An independent steering committee includ-
ing health-care professionals, academic researchers, and
service users will provide, oversee, and facilitate the
study and will meet at least twice a year. This study was
also adopted on to the UK National Cancer Research
Network Portfolio (UKCRN ID 16236), which provides
research infrastructure resources, including Clinical Trial
Officer support for recruitment.Ethics and dissemination
This study has received ethical approval from the
National Research Ethics Service (NRES) Committee
North West - Lancaster and Health Research Authority
NRES Centre - Manchester, and research and development
governance approval from two London National Health
Service (NHS) hospital trusts. Any planned changes to the
study design will be submitted for further approval by
NRES and relevant research and development committees.
We will present study findings at conferences and publish
them in peer-reviewed journals. Only individuals who fulfill
the authorship criteria will be included as authors on final
publications.
Discussion
This study will explore the feasibility and acceptability of
a community-based walking program in enhancing QoL
outcomes in people with recurrent or metastatic cancer.
To date, this is the first study investigating whether a
brief walking intervention on its own is sufficient to en-
hance the health and well-being of these people. This is
particularly important because although the number of
people living with cancer continues to increase [2]
people with recurrent or metastatic disease report re-
duced QoL [1].
Despite being the first of its kind, the intervention will
only be available in English and therefore the uptake/
views of minority ethnic groups may be underrepre-
sented. Also, eight tumor types are included in the trial
sample, which means that findings cannot be generalized
to all tumor groups.
Findings from this study will determine whether re-
cruitment to a full-scale trial is feasible and provide ini-
tial data for future sample size calculations. It will
collect information on the acceptability of the walking
intervention and permit refinement where necessary.
Furthermore, the study will assess whether the outcomes
being used are acceptable, appropriate and sensitive to
change in this population. Finally, the study will investi-
gate the acceptability of the use of pedometers and their
influence on walking behavior.
Trial status
Recruiting was closed on the 30th November 2014.
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